776 Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 4-year analysis of the C-144–01 study

Benzer Materyaller

• 776 Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 4-year analysis of the C-144–01 study
  Yazar:: James Larkin, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-11-01)
• Lifileucel tumor‐infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors
  Yazar:: Harriet Kluger, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-10-01)
• 778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma
  Yazar:: Gino K In, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-11-01)
• Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Unresectable or Metastatic Melanoma
  Yazar:: L. Karapetyan, ve diğerleri
  Baskı/Yayın Bilgisi: (2026-01-01)
• Biosafety and biohazard considerations of HSV-1–based oncolytic viral immunotherapy
  Yazar:: Elizabeth Robilotti, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-09-01)